Written by 08:00 Analys

BONZUN: A quarter of build-up for increased IVF action in H2

BONZUN The Q1’22 report showed some progress for Bonzun’s stress management service, Bonzun evolve, with an increased number of licenses and approval from the Swedish Social Insurance Agency, but reflected less activity in the other vertical, the IVF support app Bonzun IVF. This however, picked up in the beginning of Q2 with the launch of a new version, new features and a partner agreement covering the US and UK. But we have yet to see progress in the build-up of a network of IVF clinics. While sales were slow in absolute terms, the 103% revenue growth in Q1, increased influencer and network driven sales of Bonzun IVF backed by the reinforced financials following the rights issue, continues to support our expectation of an acceleration in H2’22 with a fair value of SEK 1.5-2.5 in 18-24 months.

Johan Widmark | 2022-05-24 08:00 DISCLOSURE: Emergers parent company Incirrata AB owns shares in Bonzun AB.  

This commissioned research report is for informational purposes only and is to be considered marketing communication. This research report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and Emergers is not subject to any prohibition on dealing ahead of the dissemination of investment research. This research does not constitute investment advice and is not a solicitation to buy shares. For more information, please refer to disclaimer.  
Focus on rekindling Bonzun evolve in Q1

During Q1, Bonzun initiated stage 2 of the pilot with TRR (Trygghetsrådet), consisting of about 50 clients implementing the Bonzun evolve program, a pilot that will be evaluated by end Q2. Existing customers who offer the iKBT program Bonzun evolve to their employees, such as the Helsinki School of Economics (Hanken), IVL and Loomis, increased their number of licenses, while Bonzun was also approved by the Swedish Social Insurance Agency as organizer of workplace-oriented rehabilitation support, which enables Bonzun evolve’s customers to apply for a grant for 50 percent of the cost of Bonzun’s services. While still early days, this could be an indication that Bonzun is building mometum to scale evlove, potentially as part of mandatory programs tied to social insurance benefits.

Building foundation for increased activity in IVF in H2’22

With regards to Bonzun IVF, the company now works to establish the app in the US and the UK, partly through a partnership with the brittish platform Fertility Help Hub with over 150,000 members in the US and the UK. The oppportunity to use Bonzun’s historic presence in China to roll-out on the back of the country’s new health insurance system for ART treatments has been delayed by the Covid-outbreak, but provide significant potential down the road. For the near to mid term however, we hope to see progress with building relationships with IVF clinics in order to leverage sales to end users.

Opportunities for international scalable growth

While the money from the rights issue will not be enough to support the business to positive cash flow, which we do not expect until 2024, it should be able to take the company to the next step and stronger momentum that should provide better and more favourable conditions for the next financing round. With increased monthly recurring revenue, continued growth for Bonzun evolve, partner and influencer driven marketing, increased contact with IVF clinics and potential for scalable growth in both the US and China, we continue to see support for a fair value of 1.5-2.5 SEK per share in 18–24 months.


General disclaimer and copyright
This material is not intended to be financial advice. This material has been commissioned by the Company in question and prepared and issued by Emergers, in consideration of a fee payable by the Company. Emergers standard fees are SEK 240 000 pa for the production and broad dissemination of a detailed note following by regular update notes. Fees are paid upfront in cash without recourse. Emergers may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services. Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained herein represent those of the research analyst at Emergers at the time of publication. The company has been given the opportunity to influence factual statements before publication, but forecasts, conclusions and valuation reasoning are Emergers’ own. Forward-looking information or statements contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. Exclusion of Liability: To the fullest extent allowed by law, Emergers shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained in this material. No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Emergers’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in this material may not be eligible for sale in all jurisdictions or to certain categories of investors. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision. Investment in securities mentioned: Emergers has a restrictive policy relating to personal dealing and conflicts of interest. Emergers does not conduct any investment business. Emergers parent company Incirrata AB does hold a position in the security mentioned in this report. The respective directors, officers, employees and contractors of Emergers may have a position in any or related securities mentioned in this report, subject to Emergers’ policies on personal dealing and conflicts of interest. Copyright: Copyright 2021 Incirrata AB (Emergers)

United Kingdom
This document is prepared and provided by Emergers for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the ”FPO”) (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document. This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States
Emergers relies upon the ”publishers’ exclusion” from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Emergers does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

For new research on growth stocks, sign up to our newsletter